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Abstract
MicroRNAs are important gene regulators that potentially play a profound role in tumorigenesis. Increasing evi-
dence indicates that miR-145 is a tumor suppressor capable of inhibiting breast and colon cancer cell growth both
in vitro and in vivo. However, the biological function of miR-145 in non-small cell lung cancer (NSCLC) is largely
unknown. In colon cancer cells, c-Myc is a confirmed direct target for miR-145. The aim of this work was to investi-
gate the effect of miR-145 and c-Myc on proliferation of NSCLC cells, using the NSCLC cell lines A549 and H23 as
models. We determined the expression level of miR-145 in tumor tissues relative to adjacent non-tumor tissues,
and in NSCLC cell lines relative to non-malignant lung cells. Downregulation of miR-145 was seen in tumor tissues
and the two NSCLC cell lines by real-time quantitative reverse transcription polymerase chain reaction. MTT and
focus formation assays were conducted to measure cell proliferation rates. Cell growth was inhibited and the G1/S
transition was blocked by miR-145 in transfection assays of A549 and H23 cells. We further showed that c-Myc was
a direct target for miR-145. Introduction of miR-145 dramatically suppressed the c-Myc/eIF4E pathway, which was
demonstrated to be crucial for cell proliferation in NSCLC cells. Furthermore, we found that CDK4 was regulated by
miR-145 in cell cycle control. Taken together, our study results demonstrate that miR-145 inhibits proliferation of
NSCLC cells through c-Myc. Increasing miR-145 expression may provide a novel approach for the treatment of
NSCLC.
Background
Lung cancer is the leading cause of cancer-associated
deaths worldwide, and non-small cell lung cancer
(NSCLC) accounts for almost 80% of lung cancer deaths
[1,2]. Despite improvements in surveillance and clinical
treatment strategies, the 5-year survival after curative
r e s e c t i o ni sr e p o r t e dt ob eo n l y3 0 - 6 0 %[ 3 ] .T h u s ,
searching for rationally designed and targeted agents
that mediate the initiation and progression of NSCLC
and can be used for molecular targeted therapies is
urgent and of great interest.
MicroRNA (miRNAs) are endogenously processed
non-coding RNAs that regulate gene expression by
blocking translation or decreasing mRNA stability [4,5].
Mature miRNAs comprise about 22 nucleotides, and are
derived from longer pri-miRNA and pre-miRNA
transcripts that undergo sequential processing by the
RNase III-like enzymes Drosha and Dicer [6,7]. After
maturation, miRNAs regulate gene expression by base-
pairing with mRNAs that are partially complementary to
the miRNAs, generating miRNA-associated effector
complexes. In contrast to small interfering (si)RNAs,
miRNAs typically target a cluster of genes instead of
one specific gene [8]. The binding of miRNAs to target
mRNAs leads to translational repression or decreased
mRNA stability. Emerging evidence shows that miRNAs
have a variety of functions in regulation and in control-
ling cancer initiation and progression [9]. MiRNAs can
function as tumor suppressors or oncogenes, depending
on their specific target genes [10,11]. For example, miR-
145, miR-335, miR-125b-1, miR-126, miR-15a, and miR-
16-1 are all tumor suppressors for specific cancer types
[12-15].
Recently, miR-145 was identified as a tumor-suppres-
sive miRNA that is downregulated in several cancer
types, including prostate cancer [16,17], bladder cancer
[17], colon cancer [18-20] and ovarian cancer [21].
Accordingly, miR-145 overexpression has a growth
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In this study, we investigated the expression of miR-145
in NSCLC normal and tumor tissues, and in the NSCLC
cell lines A549 and H23 and the non-malignant lung
cell line Gekko Lung-1. We used overexpression of
miR-145 to determine the effect on cellular proliferation
and the cell cycle in A549 and H23 cells. We examined
the effect of miR-145 on c-myc pathway protein expres-
sion and measured direct interaction by c-Myc binding.
Moreover, c-myc, eIF4E and CDK knockdown inhibited
cell proliferation of A549 and H23 cells. Furthermore,
we demonstrated that CDK is crucial for cell cycle pro-
gression in A549 cells. Based on our results, we postu-
late that miR-145 inhibits NSCLC cell proliferation in
part by mediating regulation of the c-myc/eIF4E
pathway.
Materials and methods
Tissue collection
Paired NSCLC and adjacent non-tumor tissues were
obtained with informed consent from 37 consecutive
patients undergoing NSCLC resection surgery between
July 2009 and March 2010 at Zhejiang Hospital of Tra-
ditional Chinese Medicine and Shanghai Changzheng
H o s p i t a l ,C h i n a .A l lt i s s u es amples were flash-frozen in
liquid nitrogen immediately after collection and stored
at -80°C until use. Both tumor and non-tumor samples
were confirmed by pathological examination. Patients
were excluded if they had recurrent NSCLC or had pri-
mary NSCLC but received chemoradiotherapy before
surgical operation [23].
Cell culture
The human NSCLC cell lines A549 and H23 were from
ATCC (ATCC# CCl-185, CRL-5800). Cells were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM;
Sigma-Aldrich, St. Louis, Mo., USA) supplemented with
10% (vol/vol) fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA, USA), 1% penicillin-streptomycin (v/v;
10,000 units/ml and 10,000 μg/ml, respectively; Invitro-
gen) and 1% Glutamax (v/v; Invitrogen). Cell cultures
were incubated at 37°C in a humidified atmosphere con-
taining 5% CO2. Stably transfected cells were cultured in
t h ep r e s e n c eo f2m g / m lp u r omycin (RocheH, Indiana-
polis, IN).
Generation of stably transfected cell lines
Single-stranded DNA oligonucleotides with human pre-
miR-145 (miRBase accession IDs MI0000461) sequences
and with restriction enzyme site overhangs were from
Integrated DNA TechnologiesH (Coralville, IA). Com-
plementary sequences were annealed and the resulting
double-stranded DNA was ligated to Xho I/Not I-
digested pLemiR vector (Open Biosystems, Huntsville,
AL). A549 cells were infected with plasmids using the
Trans-Lentiviral GIPZ packing system (Open Biosys-
tems; Huntsville, AL) according to the manufacturer’s
protocol. Briefly, TLA-HEK293TTM cells were trans-
fected using Arrest-In with 37.5 μg plasmid DNA in
serum-free medium for 4 h. Media was then replaced
with serum-containing media for 36 h. Media were col-
lected, centrifuged to remove cell debris and used to
infect A549 and H23 cells. At 48 h after addition of
virus, infected cells were selected by adding 2 mg/ml
puromycin.
Real-time RT-PCR (qPCR) for small RNA quantification
Total RNA (20 ng), isolated using a PureLink Micro-to-
Midi total RNA isolation kit (Invitrogen) according to
the manufacturer’s protocol, was reverse transcribed
using a TaqMan reverse transcription (RT) kit (Applied
Biosystems, Foster City, CA) and RNA-specific primers
with TaqMan microRNA assays (Applied Biosystems) in
15 μl, with annealing at 16°C for 30 min followed by
extension at 42°C for 30 min. From the RT reaction,
1.33 μL was combined with 1 μL specific primers for
either RNU6B or miR-145 (Applied Biosystems, Foster
City, CA) in triplicate wells for 44-cycle PCR using a
7900HT thermocycler (Applied Biosystems). Denatura-
tion at 95°C was for 15 s, and annealing and extension
at 60°C was for 1 min. SDS software (Applied Biosys-
tems, Foster City, CA) was used to determine cycle-
threshold (Ct) fluorescence values. Prism 5.0b software
(GraphPad; La Jolla, CA) was used for statistical analysis
and graphing.
c-Myc luciferase reporter assay
Cultures were transfected with 5 μg, 10 μg, or 15 μg
pBV-c-Myc-luc plasmid using Metafectene Pro. The
next day, cells were replated and incubated overnight.
Cultures were treated as indicated for 24 h and lucifer-
ase activity was determined using a luciferase kit (Pro-
mega), normalizing to protein concentration and then to
a control sample transfected with pBV-luc and treated
with DMSO.
Cell viability analysis and focus formation assay
Cell proliferation was evaluated by 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.
Briefly, cells were plated in 96-well plates with 4000
cells in 100 μl per well and incubated for 72 h. MTT
was added under sterile conditions, and the cells were
incubated for 4 h before reading absorbance at 570 nm
in an enzyme-linked immunosorbent assay plate reader.
Each experiment was performed in six replicate wells
and independently repeated three times. Absorbance
values were normalized to media control. For focus for-
mation assays, cells transfected with vector, or cells
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60-80% confluence. After 24 h, cells were trypsinized
and split into six-well dishes as described previously
[24].
Transient expression of CDK4
Cells were transfected with 5 μg human wild-type (Wt)
pCMV-cdk4 using Metafectene Pro transfection reagent
(Biontex) according to the manufacturer’sp r o t o c o l .
After 24 h, cells were replated and cultured for 24 h
before measurement.
Cell cycle analysis
Cells grown to 70%-90% confluence were detached by
trypsinization, fixed in 70% ethanol at 4°C for 1-2 days,
washed with phosphate-buffered saline (PBS), and incu-
bated at a density of 1-2 × 10
6 cells/ml with 0.3 μM 4,6-
diamidino-2-phenylindole dihydrochloride (DAPI; MP
Biochemicals, Solon, OH) in PBS at room temperature
in the dark for 100 min. After washing once with PBS,
DAPI fluorescence was assayed using an LSR II (BD
Biosciences, San Jose, CA) flow cytometer equipped
with a 408-nm violet laser diode and a 450/50 nm emis-
sion filter.
Western blot analysis
To determine protein expression levels, cells were har-
vested and lysed in RIPA lysis buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.25%
sodium deoxycholate and 1 mM EDTA) with freshly
added protease inhibitor cocktail (Roche) for 15 min on
ice, then centrifuged at 13,000 rpm for 10 min. Total
protein of clarified supernatants was quantified by
bicinchoninic acid assay (BCA) kit (Pierce Biotechnol-
ogy). To analyze protein levels, blots were blocked with
5% milk in PBST (0.05% Tween-20 in PBS) and probed
with primary antibody against c-Myc (1:500), eIF4E
(1:1000), CDK4 (1:2000), or beta-actin (1:1000) for 4 h
at room temperature or overnight at 4°C, and followed
by horseradish peroxidase-conjugated secondary anti-
body (Pierce, Rockford, IL) for 1 h at room temperature.
Protein bands were detected with SuperSignal West
Pico chemiluminescence substrate (Pierce) and pro-
cessed with the GenTools software package. In each
experiment, the same amount of protein was used, and
the experiments were repeated independently at least
three times.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed using a ChIP Assay Kit
(Upstate Biotechnology, Lake Placid, NY, USA) on A549
cells cultured to 70-80% confluence. Chromatin was
cross-linked with 1% formaldehyde at 37°C for 10 min.
Cells were washed with cold PBS twice and disrupted in
SDS lysis buffer containing protein inhibitor cocktail.
Chromatin was sonicated to an average length of 200 to
1000 bp as verified by agarose gel. Sonicated cell super-
natants were diluted 10-fold in ChIP dilution buffer
containing protein inhibitor cocktail and an aliquot was
reserved for input control. Antibody against c-Myc (10
μg, Abcam, Cambridge, MA) was added and the chro-
matin solution was gently rotated overnight on ice. Pro-
tein A agarose slurry was added and incubated at 4°C
for 1 h with constant rotation. Agarose beads were col-
lected by centrifugation and washed, and antibody-
bound chromatin released from the agarose beads. DNA
was purified by phenol/chloroform extraction and etha-
nol precipitation. Binding was detected by PCR. A 10-kb
region downstream from the binding site was used as a
negative control.
shRNA transfection
ShRNA constructs against c-Myc, eIF4E and CDK4 were
from Origene Company (Rockville, MD). A549 or H23
cells were cultured until 70%-80% confluence. Cells
were transfected with shRNA using transfection reagent
Fugene HD (Roche) according to the manufacturer’s
instructions. The level of miR-145 expression was deter-
mined using PCR.
Statistical analysis
All data are presented as mean ± standard deviation
(SD). Statistical significance was determined by two-
tailed Student’s t-test. P-values of < 0.05 were consid-
ered statistically significant. Analyses used GraphPad
Prism version 5.0 for Windows, GraphPad Software
(San Diego, CA).
Results
Expression profile of miR-145 in non-small cell lung
cancers
Prompted by numerous reports of miR-145 downregula-
tion in cancer [25-27], we sought to identify the role of
miR-145 in NSCLC. We compared the expression levels
of miR-145 in NSCLC compared to corresponding nor-
mal tissues by qPCR for miR-145 in 37 matched pairs of
tumor and non-tumor tissues from patients. We also
measured expression in a non-tumorigenic lung cell line
and two human NSCLC cell lines. As shown in Figure
1A, miR-145 expression levels were significantly
decreased in tumors compared to the paired normal
samples. Further, compared to the normal lung cell line
Gekko Lung-1, the NSCLC cell line A549 showed about
80% significantly lower expression of miR-145, and H23
NSCLC cells showed approximately 50% lower expres-
sion (Figure 1B). The reduced expression of miR-145 in
NSCLC suggested that miR-145 is a potential anti-onco-
genic miRNA in this cancer.
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human NSCLC cells
To test the function of miR-145 in cell growth, we used
miR-145 precursor miRNA to infect human NSCLC
A549 and H23 cells, both of which showed good trans-
fection efficiency. After transfection, miR-145 levels were
increased in both cell lines, indicating that enhancement
was due to the introduction of precursor miR-145 (data
not shown). As demonstrated by MTT growth assays,
overexpression of miR-145 dramatically reduced cell pro-
liferation in both cell lines (Figure 2A). To assess biologi-
cal activity, focus formation assays were performed on
A549 and H23 cells. Compared to cells transfected with
control vector, the number of colonies from A549 and
H23 cells overexpressing miR-145 decreased by about
50% and 15%, respectively (Figure 2B).
miR-145 regulates cell-cycle progression
Cell cycle analysis results showed a significant decrease
in growth after transfection to overexpress miR-145,
indicating that cell proliferation was inhibited. In addi-
tion, we found that cells transfected to overexpress
miR-145 accumulated in G1 phase. This suggested that
miR-145 regulates cell-cycle progression primarily by
delaying the G1/S transition (Figure 3).
miR-145 directly targets the c-Myc/eIF4E pathway in
human NSCLC A549 cells
c-Myc induction of eIF4E in cancer cells is frequently
used as a cellular model to study the molecular mechan-
ism of cancer proliferation, but its interaction with the
expression signature of miR-145 is not completely
understood. Therefore, we investigated if miR-145
directly regulated the c-Myc/eIF4E pathway. Examina-
tion of 37 paired tissues of NSCLC tumors and adjacent
uninvolved lung, and the NSCLC cell lines for c-Myc,
eIF4E and CDK4 expression showed enhanced levels in
tumor tissues and cancer cell lines (Figure 4A-D). We
confirmed that miR-145 downregulated c-Myc and the
c-Myc target genes eIF4E and CDK4, which are involved
in cell proliferation and cycle regulation (Figure 4E, F).
We further investigated if miR-145 directly regulated
the c-Myc/eIF4E pathway by luciferase assay and found
that overexpression of miR-145 reduced c-Myc levels.
(Figure 4G). ChIP analysis using specific c-Myc antibody
and PCR of the precipitated DNA with a primer set
confirmed the physical association of c-Myc with the
endogenous miR-145 promoter in A549 cells (Figure
4H). In contrast, a non-specific primer set to amplify a
region 11 kb downstream of the miR-145 promoter did
not produce a PCR product.
Suppression of c-Myc, eIF4E and CDK4 inhibit
proliferation of A549 and H23 cells
Previous studies have shown that c-Myc/eIF4E is impor-
tant in cellular proliferation and protein synthesis [28].
Thus, increased levels of c-Myc/eIF4E might function in
the growth advantage of tumors. To investigate the bio-
logical significance of c-Myc, eIF4E, and CDK4 in
NSCLC cells, we tested whether RNAi-mediated reduc-
tion of c-Myc, eIF4E and CDK4 levels influenced the
growth rate of A549 and H23 cells. We found that silen-
cing expression of c-Myc, eIF4E, or CDK4 significantly
decreased the growth rate of A549 and H23 cells by
35%-45% in three separate experiments (Figure 5). Over-
expression of CDK4 by transfection of a Wt pCMV-
CDK4 vector into NSCLC cell lines rescued the growth
inhibition induced by elevated expression of miR-145.
miR-145 regulated CDK4 is crucial for cell cycle
progression in A549 cells
Cell cycle analysis determined that the effect of miR-145
on cell proliferation of NSCLC cells was due to cell
cycle alterations. We tested whether RNAi-mediated
reduction in eIF4E or CDK4 levels influence the cell
progression of A549 cells and found that RNAi directed
Figure 1 Expression of miR-145 in normal tissues and non-
small cell lung cancer. miR-145 levels were measured by miRNA
TaqMan qRT-PCR in normal and in NSCLC tissue (A), and in the
normal lung cell line Gekko Lung-1, and the NSCLC cell lines A549
and H23 (B). (A) Relative levels of miR-145 were lower in tumor
tissue than in normal tissue. (B) Relative levels of miR-145 in the
NSCLC cell lines, particularly A549, were lower than in Gekko Lung-1
cells. Vertical axis indicates relative expression of each miRNA
normalized to control. Results are mean ± SD of three independent
experiments. *P < 0.05 by Student’s paired t-test compared to
untreated cells (control).
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of cells in G1 phase from 60.7% to 92.5% (P < 0.01)
(Figure 6). However, knockdown of eIF4E by siRNA did
not alter cell cycle progression of A549 cells. These
results indicated that downregulation of CDK4 by miR-
145 induced a G1 cell-cycle arrest in NSCLC cells.
Discussion
MiRNAs are frequently deregulated in malignant tissues
[29]. Recently, the expression of miRNAs such as let-7
and miR-126 were found to be frequently reduced in
lung cancer, both in vivo and in vitro,a n dr e d u c e d
expression was significantly associated with shortened
postoperative survival, independent of disease stage
[30-32]. We studied the expression profile of miR-145,
which is underexpressed in several tumor types [18,33]
and found that miR-145 was underexpressed in NSCLC
specimens compared to matched normal tissue samples
(Figure 1A), and was drastically reduced in NSCLC cell
lines compared to the non-malignant lung cell line
Gekko Lung-1. This suggested miR-145 is a potential
tumor suppressor in NSCLC. Downregulation of miR-
145 was more prominent in A549 cells than in H23
cells, indicating variability of this effect in different cell
lines. These findings prompted us to investigate the reg-
ulation of miR-145 in NSCLC cells, since differential
expression of miRNAs suggests that miRNAs may be
involved in the genesis and development of tumors.
Figure 2 miR-145 overexpression reduces the proliferative potential of A549 and H23 cells. (A) MTT assays reveal reduced cell growth for
stable transfected cell lines compared to vector-transfected control. (B) Methylene blue-stained culture plates demonstrated no difference in
adherent colony formation in six-well dishes. Values are means of three separate experiments ± SD. *P < 0.05 by Student’s paired t-test
compared to untreated cells (control).
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tumor cells, we employed the NSCLC cell lines A549
and H23. In agreement with reports showing a growth
inhibitory effect of miR-145 [19,34], we also observed a
significant growth reduction of A549 and H23 cells
upon transfection with an miR-145 expression vector,
and the most pronounced growth inhibitory effect was
seen in A549 cells. We investigated the effect of miR-
145 in the progression of cell cycle and showed that len-
tivirus-mediated expression of miR-145 induced cell
cycle arrest. MiR-145 overexpressing cells showed G0/
G1 phase arrest and S-phase reduction in both cell
lines, suggesting that the reduced growth of the cells
may be associated with cell cycle arrest.
Recent studies showed that miR-145 silenced c-Myc
and its downstream targets in colon cancer, which be
associated with c-Myc/eIF4E as a miR-145 target [19].
Interestingly, downregulation of the miR-145 in NSCLC
is consistent with upregulation of c-Myc, eIF4E and
C D K 4i nt h es a m es a m p l es e tw h i c hi sc o n s i s t e n tw i t h
our finding that c-Myc is a major target for miR-145 by
ChIP. Knock down of c-Myc, eIF4E and CDK4 respec-
tively showed that they are all important for prolifera-
tion in both cell lines. Furthermore, by silencing eIF4
Figure 3 Effect of miR-145 on A549 and H23 cell cycle. A549 and H23 cells were stablely transfected with vector control or miR-145
expression vector. After 2 days, cells were harvested for cell cycle analysis. (A) Percentage of A549 cells transfected with vector control or miR-
145 expression vector at different phases. (B) Percentage of H23 cells transfected with vector control or miR-145 expression vector cells at
different phases. Data were obtained by densitometry measurement and the mean of three experiments.
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Page 6 of 10Figure 4 miR-145 regulates the c-myc/eIF4E pathway in NSCLCs. Western blot analysis of c-myc, eIF4E, and CDK4 expression levels in
normal and tumor tissue (A, B), and one normal lung cell line and two NSCLC cell lines (C, D). (E, F) Western blot for c-myc, eIF4E, and CDK4
after transfection with pre-miR-145 expression vector and or control miRNA vector. (G) Cells transiently transfected with the empty pBV-luc
plasmid vector or pBV-c-Myc-luc plasmid were treated for 24 h. Luciferase activity was normalized to protein concentration and then to
measurements from pBV-luc-transfected, DMSO-treated control cultures. (H) ChIP assays of c-Myc binding to miR-145 DNA. The beta actin gene
was used as an internal control.
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Page 7 of 10Figure 5 Suppression of c-myc, eIF4E, andCDK4 by RNAi reduces A549 and H23 proliferation. (A) Suppression of cell proliferation by c-
myc, eIF4E and CDK siRNA in A549. (B) Suppression of cell proliferation in H23, as in part (A). A549 and H23 cells were transfected with c-myc,
eIF4E and CDK siRNA, and assayed by MTT. (C) A549 and H23 cells were transiently transfected with vector control, miR-145 expression vector or
miR-145 expression vector plus pCMV-CDK4, followed by MTT assay. Data are mean ± SD of three independent experiments. *P < 0.05 by
Student’s paired t-test compared to untreated cells (control).
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sion of cell cycle. Based on our findings, we propose
that miR-145 regulates NSCLC cell proliferation partly
by targeting c-Myc, and that the loss of miR-145 may
provide a selective growth advantage during lung
carcinogenesis.
In summary, we conducted miR-145 expression profil-
ing in human NSCLC cells, and focused on the identifi-
cation of targets of abnormally expressed miR-145. Our
results showed that miR-145 was significantly downre-
gulated and might be used as a marker for advanced
NSCLC. In addition, we also found that miR-145 tar-
geted c-Myc, which suggested an explanation for the
carcinogenesis pathway mediated by miR-145 and pro-
vided data that may contribute to molecular targeted
therapy based on miRNAs.
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